Neurobo Pharmaceuticals Earnings Estimate
| NRBO Stock | USD 3.44 0.02 0.58% |
Neurobo |
Neurobo Pharmaceuticals Earnings Estimation Breakdown
The calculation of Neurobo Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Neurobo Pharmaceuticals is estimated to be -1.25 with the future projection ranging from a low of -1.25 to a high of -1.25. Please be aware that this consensus of annual earnings estimates for Neurobo Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.25 Lowest | Expected EPS | -1.25 Highest |
Neurobo Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Neurobo Pharmaceuticals' value are higher than the current market price of the Neurobo Pharmaceuticals stock. In this case, investors may conclude that Neurobo Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Neurobo Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2024 | Current EPS (TTM) | |
| 0 | 53.13% | -2.28 | -1.25 | -2.46 |
Neurobo Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Neurobo Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Neurobo Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Neurobo Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Neurobo Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Neurobo Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Neurobo Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Neurobo Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Neurobo Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-28 | 2023-12-31 | -0.78 | -2.28 | -1.5 | 192 | ||
2023-11-13 | 2023-09-30 | -0.11 | -0.09 | 0.02 | 18 | ||
2023-08-09 | 2023-06-30 | -0.13 | -0.02 | 0.11 | 84 | ||
2023-05-12 | 2023-03-31 | -0.63 | -0.1 | 0.53 | 84 | ||
2023-03-30 | 2022-12-31 | -1.2 | -1.82 | -0.62 | 51 | ||
2022-11-14 | 2022-09-30 | -5.1 | -3.5 | 1.6 | 31 | ||
2022-08-12 | 2022-06-30 | -5.1 | -0.12 | 4.98 | 97 | ||
2022-05-13 | 2022-03-31 | -0.15 | -0.17 | -0.02 | 13 | ||
2021-11-15 | 2021-09-30 | -5.4 | -4.8 | 0.6 | 11 | ||
2021-08-16 | 2021-06-30 | -4.5 | -5.4 | -0.9 | 20 | ||
2021-05-17 | 2021-03-31 | -4.8 | -4.5 | 0.3 | 6 | ||
2020-12-31 | 2020-12-31 | -5.7 | -36.0 | -30.3 | 531 | ||
2020-11-13 | 2020-09-30 | -5.1 | -5.7 | -0.6 | 11 | ||
2020-08-11 | 2020-06-30 | -5.7 | -4.5 | 1.2 | 21 | ||
2020-05-20 | 2020-03-31 | -3 | -9.0 | -6.0 | 200 | ||
2020-03-30 | 2019-12-31 | -6 | -101.1 | -95.1 | 1585 | ||
2019-11-08 | 2019-09-30 | -0.11 | -6.0 | -5.89 | 5354 | ||
2019-08-09 | 2019-06-30 | -116.25 | -150.0 | -33.75 | 29 | ||
2019-05-09 | 2019-03-31 | -0.42 | -6.75 | -6.33 | 1507 | ||
2019-03-15 | 2018-12-31 | -307.5 | -195.0 | 112.5 | 36 | ||
2018-11-08 | 2018-09-30 | -354.37 | -322.5 | 31.87 | 8 | ||
2018-08-13 | 2018-06-30 | -409.5 | -352.5 | 57.0 | 13 | ||
2018-05-08 | 2018-03-31 | -496.87 | -435.0 | 61.87 | 12 | ||
2018-03-15 | 2017-12-31 | -519 | -472.5 | 46.5 | 8 | ||
2017-11-13 | 2017-09-30 | -511.5 | -615.0 | -103.5 | 20 | ||
2017-08-14 | 2017-06-30 | -660 | -562.5 | 97.5 | 14 | ||
2017-05-09 | 2017-03-31 | -490 | -592.5 | -102.5 | 20 | ||
2017-03-15 | 2016-12-31 | -406.87 | -585.0 | -178.13 | 43 | ||
2016-11-02 | 2016-09-30 | -335 | -420.0 | -85.0 | 25 |
About Neurobo Pharmaceuticals Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Neurobo Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Neurobo Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Neurobo Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -108.3 M | -102.9 M | |
| Retained Earnings Total Equity | -59.9 M | -62.9 M | |
| Earnings Yield | (0.66) | (0.70) | |
| Price Earnings Ratio | (1.50) | (1.58) | |
| Price Earnings To Growth Ratio | 0.02 | 0.02 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neurobo Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neurobo Pharmaceuticals' short interest history, or implied volatility extrapolated from Neurobo Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.Note that the Neurobo Pharmaceuticals information on this page should be used as a complementary analysis to other Neurobo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Neurobo Stock analysis
When running Neurobo Pharmaceuticals' price analysis, check to measure Neurobo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobo Pharmaceuticals is operating at the current time. Most of Neurobo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neurobo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurobo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neurobo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Neurobo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Return On Assets (0.35) | Return On Equity (0.65) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.